September 26, 2014 9:03 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
GlycoMimetics, Inc.(Nasdaq: GLYC) announced today that it has been informed by Pfizer (NYSE: PFE),the company responsible for ongoing clinical development of rivipansel, thatinitiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will besignificantly delayed due to a manufacturing development issue impactingformulated drug supply. Pfizer advised GlycoMimetics that the issue is underreview and Pfizer is working diligently to remedy the situation. Pfizer alsonoted that upon identifying the specific cause and associated remedy of themanufacturing issue, Pfizer will advise GlycoMimetics of a more specifictimeframe regarding the commencement of the Phase 3 study.GlycoMimetics has previously reported that it expected commencement of thetrial before the end of 2014. GlycoMimetics entered into an exclusive licenseagreement with Pfizer for rivipansel in October 2011. The companies areinitially developing rivipansel as a potential treatment for vaso-occlusivecrisis of sickle cell disease (VOC). Under the license agreement, Pfizer isresponsible for the clinical development, regulatory approval and potentialcommercialization of rivipansel.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.